![Memorial Sloan Kettering Medical Oncologist Komal Jhaveri](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/node/102722/3x2/jhaveri-komal-220407-07_rt_1200x800.jpg?h=10d202d3)
Komal Jhaveri, MD, FACP
Breast Medical Oncologist & Early Drug Development Specialist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Request an Appointment
About Me
- Section Head, Endocrine Therapy Research Program
- Clinical Director, Early Drug Development Service
- Patricia and James Cayne Chair for Junior Faculty
I am a medical oncologist dedicated to caring for people with breast cancer. Each year, I provide care to approximately 300 people across Memorial Sloan Kettering Cancer Center (MSK) in Manhattan and the David H. Koch Center for Cancer Care.
I am fortunate to have a career that I’m passionate about and that allows me to help so many people, both in the clinic and through research that may impact cancer care in the future.
Read more
When patients first meet with me, I take time to address their concerns about their diagnosis and answer their questions regarding treatment and prognosis. I try to lessen their anxiety and earn their trust so they feel comfortable in my presence. It is important to me that patients know they are in good hands with me, and with their experienced clinical care team, which includes a registered nurse, a nurse practitioner, or a physician assistant. When needed, I also refer patients to a social worker, a support group, and/or integrative medicine services. These resources can help patients cope and improve their overall wellbeing.
Some people may wonder if they did something wrong or are somehow responsible for developing cancer, but I reassure them that it is not their fault. Whether a person has early-stage disease or their cancer has metastasized (spread), I help them focus on what we can do and encourage them with information about research developments and new treatment options that may benefit them. We talk about exciting advances in the field that have led to our ability to cure patients, achieve long-term remissions, and prolong survival while maintaining quality of life, even for those with late-stage disease. In instances when patients are not able to receive treatment or do not wish to pursue therapy, I help them navigate those decisions.
Medical oncology is a unique subspecialty because it allows doctors and patients to cultivate close relationships and, in most cases, requires continuity of care. I chose this field not only because I wanted to understand the science and biology behind what drives cancer while working to find a cure or ways to improve patient outcomes, but also to develop long-term relationships with patients and their families. Patients let me into the most intimate aspects of their lives; I am privileged to be able to celebrate their happy moments and, in other instances, to guide them and their loved ones through very difficult times.
At MSK, I conduct translational research in collaboration with my laboratory colleagues to shepherd our findings from the lab to the clinic. Through my research, I aim to accelerate the development of new treatments and improve outcomes for people with breast cancer. Our latest work involves the use of acquired biospecimen (cell-free DNA and tumor) analyses and imaging studies to identify and understand biomarkers indicating response or resistance to breast cancer treatment.
As the section head for the Endocrine Therapy Research Program, I manage the clinical trial portfolio for hormone receptor-positive HER2-negative/low breast cancer. I am currently involved with trials evaluating novel PI3K inhibitors, new endocrine drugs used alone or in combination with other drugs, and antibody drug conjugates, among other investigational therapies. I also serve as the Clinical Director for the Early Drug Development Service. This work positions me as the principal investigator for many exciting phase 1 trials led by this service.
Outside of work, I enjoy traveling and playing board games with my family. I also like to relax by participating in my book club and stay active by skiing, dancing, and playing tennis.
A breast oncologist is a doctor with special training in breast cancer.
An early drug development specialist tests new drugs to treat cancer. They have special training in research studies, known as clinical trials.
My Specialties
- Breast Cancer
- Early-Phase Clinical Trials
Education
- MD, University of Mumbai
Residencies
- Nuclear Medicine - Radiation Medicine Center/Tata Memorial Hospital
- Internal Medicine - St. Luke's-Roosevelt Hospital Center/Columbia University
Fellowships
- Hematology/Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
![Women talking](https://www.mskcc.org/sites/default/files/styles/width_600_1x1/public/paragraph/131881/cta_image/app-220128-006_rt_1200x800.jpeg?h=10d202d3)
New Patients
Current Patients
Contact and Location
Dr. Jhaveri sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Jhaveri
- A Phase 1 Study of ABBV-400 in People With Advanced Solid Tumors
- A Phase 1b/2 Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Advanced Breast Cancer
- A Phase I Study of DS-1062a in People with Advanced Digestive Cancers
- A Phase I Study of RLY-2608 Alone in People with Solid Tumors or in Combination with Fulvestrant in People with Breast Cancer
![Smiling doctors in the lab](/themes/mskcc/images/clinicaltrials_small.png)
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Jhaveri K, Juric D, Yap Y, Cresta S, Layman R, Duhoux F, Terret C, Takahashi S, Huober J, Kundamal N, Sheng Q, Balbin A, Ji Y, He W, Crystal A, De Vita S, Curigliano G. A phase 1 study of LSZ102, an oral selective estrogen receptor degrader, with or without ribociclib or alpelisib in patients with estrogen receptor-positive breast cancer. Clin Cancer Res. 2021;27(21):5760-70. PMID: 34433648
Jhaveri K, Drago J, Shah P, Wang R, Pareja F, Ratzon F, Iasonos A, Patil S, Rosen N, Fornier M, Sklarin N, Chandarlapaty S, and Modi S A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer. Clin Cancer Res. 2021;27(14):3867-3875. PMID: 33947692
Jhaveri K, dos Anjos CH, Taldone T, Wang R, Comen E, Fornier M, Bromberg J, Ma W, Patil S, Rodina A, Pillarsetty N, Duggan S, Khoshi S, Kadija N, Chiosis G, Dunphy M, Modi S. Measuring tumor epichaperome expression using [124I] PU-H71 positron emission tomography as a biomarker of response for PU-H71 plus nab-paclitaxel in HER2-negative metastatic breast cancer. JCO Precision Oncology. 2020;4:PO.20.00273. PMCID: PMC7713524
Jhaveri K*, Wang XV, Makker V, Luoh S-W, Mitchell E-P, Zwiebel J-A, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O’Dwyer PJ, Chen AP, Flaherty KT. Ado-trastuzumab emtansine (T-DM1) inpatients with HER2-amplifiedtumors excluding breast and gastric/gastroesophageal junction(GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q. Ann of Oncol. 2019;30(11):1821–30. PMCID: PMC6927318
Jhaveri K, Chang M , Juric D, Saura C, Gambardella V, Melnyk A, Patel M, Ribrag V, Ma C, Aljumaily R, Bedard P, Sachdev J, Dunn L, Won H, Bond J, Jones S, Savage H, Scaltriti M, Wilson T, Wei M, Hyman D. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers. Clin Cancer Res. 2020 Nov 4; clincanres.2657.2020
Visit PubMed for a full listing of Dr. Jhaveri’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Komal Jhaveri discloses the following relationships and financial interests:
-
Aptitude Health
Professional Services and Activities -
AstraZeneca
Professional Services and Activities -
AstraZeneca UK Limited
Professional Services and Activities -
Blueprint Medicines
Professional Services and Activities -
Bristol-Myers Squibb
Professional Services and Activities -
Cancer Expert Now, Inc.
Professional Services and Activities -
Clinical Education Alliance, LLC
Professional Services and Activities -
Curio Science LLC
Professional Services and Activities -
Daiichi Sankyo
Professional Services and Activities -
EcoR1 Capital LLC
Professional Services and Activities -
GE Healthcare
Professional Services and Activities -
Genzyme
Professional Services and Activities
-
Gilead Sciences, Inc.
Professional Services and Activities -
Intellisphere, LLC
Professional Services and Activities -
Loxo Oncology
Professional Services and Activities -
Medscape
Professional Services and Activities -
Novartis Pharmaceuticals Corporation
Professional Services and Activities -
OncLive
Professional Services and Activities -
Oncology Specialty Group
Professional Services and Activities -
Physicians' Education Resource
Professional Services and Activities -
Rain Therapeutics Inc.
Professional Services and Activities -
Roche
Professional Services and Activities -
Scorpion Therapeutics, Inc.
Professional Services and Activities -
Stemline Therapeutics, Inc.
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].